

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

28 Jun 2026

### **Efficacy of Barley water (*Hordeum vulgare*) in clinical outcome of COVID-19 patients hospitalized in Shiraz: a single blind, randomized controlled clinical study**

#### **Protocol summary**

##### **Study aim**

Determining the effect of Barley water in the treatment of clinical symptoms of patients with COVID-19 admitted to Shiraz hospitals

##### **Design**

Randomized clinical trial with control group , single blind, phase 2, on 100 patients. Random allocation software 2.0 uses for randomization.

##### **Settings and conduct**

The study site is Shiraz hospitals which is selected for patients with Covid-19. The study is single blind. The product is given by the nurse and the researcher is blinded. The duration of use of this product is 14 days. Patients follow up is done for the duration of hospitalization.

##### **Participants/Inclusion and exclusion criteria**

Inclusion criteria: Patients with a definitive diagnosis of pneumonia (pneumonitis) caused by COVID 19; Patients are not in the severe group and do not need care in the intensive care unit (ICU care); age > 18; Patients don't receive antiviral medication prior to enrollment; The disease is confirmed by PCR or CT scan. Exclusion criteria :Pregnancy; chronic kidney disease; history of allergy to barley.

##### **Intervention groups**

One hundred patients are selected from the target population and randomly divided into two equal groups. Patients in both groups receive current medications for this disease according to the approved protocol, but patients in the intervention group also receive a 250 cc glass of barley water daily (around 11 am).

##### **Main outcome variables**

clinical symptoms; duration of recovery of each of the clinical symptoms; rate of improvement of clinical symptoms; duration of hospitalization

#### **General information**

##### **Reason for update**

##### **Acronym**

##### **IRCT registration information**

IRCT registration number: **IRCT20150830023823N3**

Registration date: **2020-12-06, 1399/09/16**

Registration timing: **registered\_while\_recruiting**

Last update: **2020-12-06, 1399/09/16**

Update count: **0**

##### **Registration date**

2020-12-06, 1399/09/16

##### **Registrant information**

##### **Name**

Ali Tavakoli

##### **Name of organization / entity**

##### **Country**

Iran (Islamic Republic of)

##### **Phone**

+98 71 3233 1028

##### **Email address**

tavakkolia@sums.ac.ir

##### **Recruitment status**

**Recruitment complete**

##### **Funding source**

##### **Expected recruitment start date**

2020-11-15, 1399/08/25

##### **Expected recruitment end date**

2020-12-13, 1399/09/23

##### **Actual recruitment start date**

empty

##### **Actual recruitment end date**

empty

##### **Trial completion date**

empty

## Scientific title

Efficacy of Barley water (*Hordeum vulgare*) in clinical outcome of COVID-19 patients hospitalized in Shiraz: a single blind, randomized controlled clinical study

## Public title

Efficacy of Barley water (*Hordeum vulgare*) in clinical outcome of COVID-19 patients

## Purpose

Treatment

## Inclusion/Exclusion criteria

### Inclusion criteria:

Patients with a definitive diagnosis of pneumonia (pneumonitis) caused by COVID 19 according to the national guidelines for the new corona virus that hospitalized in selected hospitals for corona virus in Shiraz. Patients are not in the severe group and do not need care in the intensive care unit (ICU care) age>18 Patients don't receive antiviral medication prior to enrollment. The disease is confirmed by PCR or CT scan.

### Exclusion criteria:

Pregnancy Chronic kidney disease History of allergy to barley

## Age

From **18 years** old

## Gender

Both

## Phase

3

## Groups that have been masked

- Investigator
- Data analyser

## Sample size

Target sample size: **50**

## Randomization (investigator's opinion)

Randomized

## Randomization description

Randomization method: we use permutation block randomization method with block size of 4. Selected samples based on these blocks are placed in intervention (A) and control (B) groups. 1. AABB 2. ABAB 3. ABBA 4. BBAA 5. BABA 6. BAAB

## Blinding (investigator's opinion)

Single blinded

## Blinding description

The product is given by the nurse and the Investigator is blinded.

## Placebo

Not used

## Assignment

Parallel

## Other design features

## Secondary Ids

empty

## Ethics committees

## 1

### Ethics committee

#### Name of ethics committee

Ethics committee of Shiraz University of Medical Sciences

#### Street address

Zand street

#### City

Shiraz

#### Province

Fars

#### Postal code

7183883477

#### Approval date

2020-05-05, 1399/02/16

#### Ethics committee reference number

IR.SUMS.REC.1399.216

## Health conditions studied

## 1

### Description of health condition studied

COVID-19

### ICD-10 code

U07.1

### ICD-10 code description

COVID-19, virus identified

## Primary outcomes

## 1

### Description

Fever

### Timepoint

Before and after the intervention In the form of daily

### Method of measurement

Thermometer

## 2

### Description

Cough

### Timepoint

daily

### Method of measurement

Patient history

## 3

### Description

Respiratory rate

### Timepoint

daily

### Method of measurement

visual by nurse

## 4

### Description

Chills

**Timepoint**

daily

**Method of measurement**

Patient history

**5****Description**

Body pain

**Timepoint**

daily

**Method of measurement**

Patient history with Visual Analog Scale

**6****Description**

duration of hospitalization

**Timepoint**

daily

**Method of measurement**

patient chart

**Secondary outcomes****1****Description**

duration of recovery of each of the clinical symptoms( fever, dry cough, respiratory rate)

**Timepoint**

daily

**Method of measurement**

clinical symptoms registration form according to the national guidelines of the new corona virus

**2****Description**

side effect such as nausea, bloating and constipation

**Timepoint**

daily

**Method of measurement**

drug side effect registration form

**3****Description**

CRP

**Timepoint**

Start and end of the intervention

**Method of measurement**

Biochemical Auto analyzer Instrument

**Intervention groups****1****Description**

Intervention group: current medications for this disease according to the approved protocol, in addition to 250 cc of barley water daily (around 11 am).

**Category**

Treatment - Other

**2****Description**

Control group: current medications for this disease according to the approved protocol

**Category**

Treatment - Drugs

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Ali Asghar Hospital

**Full name of responsible person**

Ali Tavakoli

**Street address**

Meshkin Fam Street

**City**

Shiraz

**Province**

Fars

**Postal code**

71439-18796

**Phone**

+98 71 3228 8602

**Email**

aliasghar@sums.ac.ir

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Shiraz University of Medical Sciences

**Full name of responsible person**

Abbas Rezaianzadeh

**Street address**

Zand St.

**City**

Shiraz

**Province**

Fars

**Postal code**

71348-14336

**Phone**

+98 71 3235 7282

**Email**

vcrdep@sums.ac.ir

**Web page address****Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Shiraz University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding***empty***Country of origin****Type of organization providing the funding**

Academic

**Person responsible for general inquiries****Contact****Name of organization / entity**

Shiraz University of Medical Sciences

**Full name of responsible person**

Ali Tavakoli

**Position**

Assistant Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Traditional Medicine

**Street address**

Zand street

**City**

Shiraz

**Province**

Fars

**Postal code**

7134845794

**Phone**

+98 71 3234 5145

**Email**

tavakkolia@sums.ac.ir

**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Shiraz University of Medical Sciences

**Full name of responsible person**

Ali Tavakoli

**Position**

Assistant Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Traditional Medicine

**Street address**

Zand street

**City**

Shiraz

**Province**

Fars

**Postal code**

7134845794

**Phone**

+98 71 3234 5145

**Email**

tavakkolia@sums.ac.ir

**Person responsible for updating data****Contact****Name of organization / entity**

Shiraz University of Medical Sciences

**Full name of responsible person**

Ali Tavakoli

**Position**

Assistant Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Traditional Medicine

**Street address**

Zand street

**City**

Shiraz

**Province**

Fars

**Postal code**

7134845794

**Phone**

+98 71 3234 5145

**Email**

tavakkolia@sums.ac.ir

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Not applicable